Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Clinical trial NCT05286437 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05286437
- Sponsor
- National Cancer Centre, Singapore
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-15
- Primary completion
- 2026-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.